文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A source of hope for platinum-resistant ovarian cancer?

作者信息

Blagden Sarah P, Nicum Shibani

机构信息

Department of Oncology, University of Oxford, Oxford, OX3 7DG, UK.

Churchill Hospital, Oxford University NHS Foundation Trust, Oxford, UK.

出版信息

Lancet. 2021 Jan 23;397(10271):254-256. doi: 10.1016/S0140-6736(21)00128-8.

DOI:10.1016/S0140-6736(21)00128-8
PMID:33485431
Abstract
摘要

相似文献

[1]
A source of hope for platinum-resistant ovarian cancer?

Lancet. 2021-1-23

[2]
WEE1 inhibition after platinum resistance.

Nat Rev Clin Oncol. 2021-4

[3]
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.

Health Technol Assess. 2015-1

[4]
The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.

Anticancer Drugs. 2014-3

[5]
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.

J Ovarian Res. 2014-4-9

[6]
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

J Clin Oncol. 2009-11-9

[7]
Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

Eur J Gynaecol Oncol. 2017

[8]
Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).

Cancer Chemother Pharmacol. 2017-12

[9]
Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.

Tumori. 2015

[10]
Activity of gemcitabine in platinum-resistant ovarian germ cell cancer.

Eur J Cancer. 1996-7

引用本文的文献

[1]
The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models.

Front Pharmacol. 2024-8-7

[2]
A nanocomposite competent to overcome cascade drug resistance in ovarian cancer mitochondria dysfunction and NO gas synergistic therapy.

Asian J Pharm Sci. 2023-11

[3]
A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer.

Cancers (Basel). 2022-9-1

[4]
Novel Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research.

Front Oncol. 2022-3-25

[5]
Phenotypic Consequences of Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer.

Cancers (Basel). 2021-11-11

[6]
Bioactive Hexapeptide Reduced the Resistance of Ovarian Cancer Cells to DDP by Affecting HSF1/HSP70 Signaling Pathway.

J Cancer. 2021-8-24

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索